Effects of Losartan on Left Ventricular Hypertrophy and Fibrosis in Patients With Nonobstructive Hypertrophic Cardiomyopathy

JACC: Heart Failure

Volumn 1, Issue 6, 2013, Pages 480-487

  Shimada, Yuichi J ^a   Passeri, Jonathan J ^b   Baggish, Aaron L ^b   O'Callaghan, Caitlin ^b   Lowry, Patricia A ^b   Yannekis, Gia ^b   Abbara, Suhny ^b   Ghoshhajra, Brian B ^b   Rothman, Richard D ^b   Ho, Carolyn Y ^a   Januzzi, James L ^b   Seidman, Christine E ^a,c   Fifer, Michael A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Angiotensin II receptor blocker; Cardiac magnetic resonance imaging; Hypertrophic cardiomyopathy; Late gadolinium enhancement; Left ventricular fibrosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LOSARTAN; PLACEBO; VERAPAMIL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CARDIAC IMAGING; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DOPPLER DEVICE; DOPPLER ECHOCARDIOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HUMAN; HYPERKALEMIA; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; KIDNEY FAILURE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNSPECIFIED SIDE EFFECT; COMPARATIVE STUDY; COMPLICATION; DRUG ADMINISTRATION; FIBROSIS; HEART MUSCLE; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CARDIOMYOPATHY, HYPERTROPHIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROSIS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MYOCARDIUM; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 84889091885     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.09.001     Document Type: Article

References (27)

1. Maron B.J., Shirani J., Poliac L.C., Mathenge R., Roberts W.C., Mueller F.O. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles. JAMA 1996, 276:199-204.
2. Varnava A.M., Elliott P.M., Sharma S., McKenna W.J., Davies M.J. Hypertrophic cardiomyopathy: the interrelation of disarray, fibrosis, and small vessel disease. Heart 2000, 84:476-482.
3. Elliott P.M., Gimeno Blanes J.R., Mahon N.G., Poloniecki J.D., McKenna W.J. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001, 357:420-424.
4. Olivotto I., Gistri R., Petrone P., Pedemonte E., Vargiu D.G., Ecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. JAm Coll Cardiol 2003, 41:315-321.
5. Green J.J., Berger J.S., Kramer C.M., Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. J Am Coll Cardiol Img 2012, 5:370-377.
6. Todiere G., Aquaro G.D., Piaggi P., et al. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy. JAm Coll Cardiol 2012, 60:922-929.
7. Kim J.B., Porreca G.J., Song L., et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 2007, 316:1481-1484.
8. Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000, 355:58-60.
9. Teekakirikul P., Eminaga S., Toka O., et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. JClin Invest 2010, 120:3520-3529.
10. Lim D.S., Lutucuta S., Bachireddy P., et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001, 103:789-791.
11. Kawano H., Toda G., Nakamizo R., Koide Y., Seto S., Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 2005, 69:1244-1248.
12. Yamazaki T., Suzuki J., Shimamoto R. Anew therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. Int Heart J 2007, 48:715-724.
13. Penicka M., Gregor P., Kerekes R., et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. JMol Diagn 2009, 11:35-41.
14. Araujo A.Q., Arteaga E., Ianni B.M., Buck P.C., Rabello R., Mady C. Effect of losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. Am J Cardiol 2005, 96:1563-1567.
15. Gersh B.J., Maron B.J., Bonow R.O., et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy. JAm Coll Cardiol 2011, 58:e212-e260.
16. Díez J., Querejeta R., López B., et al. Losartan-dependent regression ofmyocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002, 105:2512-2517.
17. Dieplinger B., Januzzi J.L., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma-the Presage ST2 assay. Clin Chim Acta 2009, 409:33-40.
18. Shah R.V., Chen-Tournoux A.A., Picard M.H., van Kimmenade R.R., Januzzi J.L. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
19. Lang R.M., Bierig M., Devereux R.B., et al. Recommendations for chamber quantification. JAm Soc Echocardiogr 2005, 18:1440-1463.
20. Nagueh S.F., Appleton C.P., Gillebert T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. JAm Soc Echocardiogr 2009, 22:107-133.
21. Harrigan C.J., Peters D.C., Gibson C.M., et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 2011, 258:128-133.
22. Moon J.C., Reed E., Sheppard M.N., et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. JAm Coll Cardiol 2004, 43:2260-2264.
23. O'Hanlon R., Grasso A., Roughton M., et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 56:867-874.
24. Bruder O., Wagner A., Jensen C.J., et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. JAm Coll Cardiol 2010, 56:875-887.
25. Lutucuta S., Tsybouleva N., Ishiyama M., et al. Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. JAm Coll Cardiol 2004, 44:2221-2230.
26. Moravsky G., Ofek E., Rakowski H., et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. J Am Coll Cardiol Img 2013, 6:587-596.
27. Ho C.Y., López B., Coelho-Filho O.R., et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. NEngl J Med 2010, 363:552-563.